Compounded GLP-1 Medications: What the FDA Crackdown Means for You

If you have been using a compounded version of semaglutide or tirzepatide for weight loss, the last few months have probably been confusing. The FDA announced a crackdown. Hims pulled its compounded GLP-1 pill after just days on the market. Novo Nordisk sued, then settled. Warning letters went out to 30 telehealth companies. And through all of it, the 1.5 million Americans estimated to be using compounded GLP-1 medications have been left wondering: is what I am taking safe, is it even legal, and what are my options now?

I have spent weeks researching the FDA statements, the clinical safety data, the legal filings and the settlement details to put together the most complete, unbiased picture I can. This is not a pro-pharma or anti-compounding article. It is a consumer-focused guide to help you understand what has changed, what the data says about safety and what your realistic options are going forward.

Disclaimer: Links may contain affiliate links, which means we may get paid a commission at no additional cost to you if you purchase through this page. Read our full disclosure here. This article is for informational purposes only and is not medical advice. Always consult your healthcare provider before starting, stopping or switching any medication.

What Are Compounded GLP-1 Medications?

Before diving into what has changed, it helps to understand what compounded drugs actually are, because they are frequently confused with both generic drugs and counterfeit drugs. They are neither.

Compounding is the practice of a licensed pharmacy mixing or altering drug ingredients to create a customized medication for an individual patient. It has been a legitimate part of pharmacy for decades. A compounded medication might be appropriate when a patient is allergic to an inactive ingredient in the commercial product, needs a different dose than what is commercially available, or when the FDA-approved version is in shortage and patients cannot access it.

Compounded drugs are not the same as generics. Generic drugs are FDA-approved copies of brand-name drugs whose patents have expired. They undergo rigorous review for safety, effectiveness and quality. GLP-1 receptor agonists like semaglutide are still under patent protection in the United States through 2032, so there are no legal generic versions available.

Compounded drugs are also not FDA-approved. This is the critical distinction. The FDA does not review compounded medications for safety, effectiveness or quality before they reach patients. They are regulated primarily at the state level by pharmacy boards, with some federal oversight depending on the type of compounder.

How We Got Here: A Timeline

The story of compounded GLP-1s starts with a genuine access problem and ends with a regulatory reckoning. Here is how it unfolded.

In 2022 and 2023, demand for semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) exploded. Manufacturers could not keep up. The FDA placed both drugs on its official drug shortage list, which activated a legal provision allowing compounding pharmacies to produce versions of the medications to fill the gap.

Compounders stepped in and offered semaglutide and tirzepatide at dramatically lower prices than the brand-name products, often through telehealth platforms. For many patients who could not afford or access the branded medications, this was the only way to get treatment. The compounding market grew rapidly.

In October 2024, the FDA determined that the tirzepatide shortage was resolved. In February 2025, the semaglutide shortage was also declared resolved. Under federal law, once a shortage is resolved, compounding pharmacies are supposed to wind down production of those medications. The FDA gave a grace period, setting deadlines in May 2025 for compounders to stop.

But many compounders did not stop. Instead, they began adding extra ingredients like B vitamins or levocarnitine to their formulations, arguing that the additions made their products different enough from the FDA-approved drugs to continue legally. Prescriptions for compounded GLP-1s actually increased after the shortage ended, according to an October 2025 IQVIA report.

In September 2025, the FDA began sending warning letters to telehealth companies for misleading advertising of compounded GLP-1 products. By March 2026, a second wave of 30 warning letters went out. The FDA also referred Hims and Hers to the Department of Justice for investigation.

In February 2026, the FDA announced it would restrict the active pharmaceutical ingredients used in mass-marketed compounded GLP-1 drugs, signaling that enforcement was escalating beyond warning letters to potential seizures and injunctions.

Then on March 9, 2026, Novo Nordisk and Hims reached a settlement. Novo dropped its patent lawsuit. Hims agreed to stop advertising compounded GLP-1 products and instead began offering branded Ozempic and Wegovy through its telehealth platform and FDA Commissioner Marty Makary publicly endorsed the deal.

What the Safety Data Actually Shows

This is the section I think matters most, and it is where the conversation usually devolves into either “compounded drugs are perfectly fine, Big Pharma just wants your money” or “compounded drugs will kill you.” The data tells a more nuanced story.

A pharmacovigilance study published in Expert Opinion on Drug Safety in 2026 analyzed the FDA's Adverse Event Reporting System (FAERS) data from 2018 to 2024, comparing safety reports between compounded and non-compounded GLP-1 receptor agonists. The findings are worth reading carefully.

Compounded GLP-1 medications were associated with higher odds of adverse events including abdominal pain, nausea, diarrhea and gallbladder inflammation compared to the FDA-approved versions. Prescribing and preparation errors were reported more frequently in the compounded group. Hospitalization rates were higher among patients using compounded products. The researchers also flagged higher reporting of suicidality in the compounded group, though they emphasized this was an observational finding that does not establish causation.

The study's authors noted that these results should be interpreted with caution. FAERS data has known limitations including underreporting (many state-licensed compounders are not required to submit adverse event reports) and reporting bias. But the overall pattern, more errors, more quality issues, more hospitalizations, is consistent with what you would expect from medications that are not subject to the same manufacturing controls as FDA-approved products.

It is also important to understand that not all compounded products come from the same source. There is a significant difference between a prescription filled by a state-licensed compounding pharmacy using active ingredients from FDA-registered manufacturers and products purchased through unregulated online sellers, overseas suppliers, or grey market channels with no verifiable chain of custody.

Some products marketed as “compounded semaglutide” may contain semaglutide salt forms that are not the same active ingredient used in the FDA-approved drugs, may be manufactured in facilities with no regulatory oversight, or may not contain what the label claims at all. The FDA has identified fraudulent products labeled with nonexistent pharmacy names or the names of licensed pharmacies that had no involvement in producing them.

If you cannot verify that your compounded GLP-1 product was prescribed by a licensed provider, filled by a state-licensed pharmacy, and sourced from an FDA-registered ingredient manufacturer, the safety profile is genuinely unknown.

Separately, the FDA has documented specific safety events including multiple reports of adverse events requiring hospitalization related to dosing errors with compounded injectable semaglutide. These errors came from both patients measuring incorrect doses and healthcare professionals miscalculating doses. Some patients received doses beyond what is used in the FDA-approved products.

Specific FDA Safety Concerns

Beyond the aggregate data, the FDA has identified several specific issues with compounded GLP-1 products that are worth knowing about if you are currently using one or considering one.

Some compounded products contain semaglutide salt forms (semaglutide sodium, semaglutide acetate) rather than the active ingredient used in the FDA-approved drugs. The FDA has stated that these are different active ingredients and that the agency does not have information on whether they have the same properties as the approved form. In practical terms, this means a compounded product labeled “semaglutide” may not contain the same molecule that was tested in the clinical trials showing safety and efficacy.

Cold chain integrity is another concern. Injectable GLP-1 drugs require refrigeration. The FDA has received complaints about compounded products arriving warm or with insufficient ice packs, which can degrade the medication's quality. If you receive an injectable GLP-1 that is not properly refrigerated, the FDA recommends not using it.

Fraudulent products have also been identified. Some compounded products are labeled with false information, including nonexistent pharmacy names or the names of licensed pharmacies that did not actually compound the drug. This makes it difficult for patients to verify what they are actually receiving.

Finally, some compounds have been marketed with added ingredients like B vitamins or levocarnitine. While these additions are sometimes presented as beneficial (reducing nausea, supporting muscle), there is no clinical evidence supporting their use in combination with semaglutide, and the safety of these specific combinations has not been tested.

The Novo Nordisk and Hims Settlement: What It Means

The March 9, 2026 settlement between Novo Nordisk and Hims and Hers is significant because it may serve as a template for how the broader compounding landscape resolves.

Under the deal, Hims agreed to offer FDA-approved Ozempic and Wegovy (including the new Wegovy pill) through its telehealth platform at established self-pay prices. In exchange, Novo Nordisk dropped its patent infringement lawsuit, though it reserved the right to refile. Hims will stop advertising compounded GLP-1 products and existing patients on compounded semaglutide will have the opportunity to transition to FDA-approved medications.

FDA Commissioner Makary publicly endorsed the deal, calling it a model for expanded patient access through legitimate channels. This is notable because it signals the FDA's preferred direction: not eliminating telehealth access to GLP-1s, but channeling that access through FDA-approved products rather than compounded alternatives.

For consumers, the practical takeaway is that Hims (one of the largest telehealth providers of compounded GLP-1s) is transitioning its business model away from compounding entirely. Other telehealth platforms may follow the same path, either voluntarily or under regulatory pressure.

The Current Landscape: What Is Legal Right Now

As of March 2026, the legal status of compounded semaglutide and tirzepatide is in flux and this section may change as enforcement actions proceed. Here is the current state of affairs.

The semaglutide shortage was officially resolved in February 2025. The tirzepatide shortage was resolved in October 2024. Under federal law, once a drug shortage is resolved, compounders are generally required to stop producing copies of the FDA-approved product. The FDA has been enforcing this with increasing intensity.

Traditional compounding (a licensed pharmacy filling a patient-specific prescription for an individual whose medical needs cannot be met by a commercially available product) remains legal under Section 503A of the Federal Food, Drug, and Cosmetic Act. What the FDA is targeting is mass-marketed compounding, where companies produce large quantities of GLP-1 medications and sell them direct-to-consumer as cheaper alternatives to the branded drugs.

The legal landscape is also complicated by ongoing litigation. The Outsourcing Facilities Association sued the FDA in early 2025 over the semaglutide shortage resolution, and some court orders have temporarily extended compounding timelines in certain jurisdictions. This means the exact rules may differ depending on your state and the type of pharmacy involved.

The bottom line: if you are currently using a compounded GLP-1, talk to your prescribing provider about your specific situation. Do not assume that what was legal six months ago is still legal today.

Your Options if You Are on a Compounded GLP-1

If you are one of the estimated 1.5 million Americans currently using a compounded GLP-1 medication, here are your realistic options as of early 2026.

The first option is to transition to a branded product with insurance coverage. If your insurance covers Wegovy, Ozempic, Zepbound or Mounjaro, this is typically the most straightforward path. Your provider may need to submit a prior authorization and not all plans cover GLP-1s for weight loss, but coverage has been expanding. Start by calling your insurance company to ask about your specific plan's coverage.

The second option is to use a branded product at a self-pay price. The Wegovy pill launched in January 2026 at $149 per month for the starting dose through Novo Nordisk savings programs. GoodRx lists introductory pricing at $149 per month for the first two fills. While this is more expensive than most compounded options, it is significantly lower than the previous self-pay cost of injectable Wegovy and represents a genuine shift in accessibility.

The third option is to access branded products through telehealth platforms. Following the Novo/Hims settlement, Hims and other telehealth providers are beginning to offer FDA-approved GLP-1 medications at competitive self-pay prices. This preserves the convenience of telehealth prescribing while using FDA-approved products.

The fourth option, if cost is the primary barrier, is to focus on the nutrition and exercise strategies that make weight management effective with or without medication. A structured GLP-1 diet plan with adequate protein, resistance training and lifestyle consistency can produce meaningful results. Adequate protein intake, strength training and creating healthier habits are the foundation regardless of whether you use medication.

Questions to Ask Your Healthcare Provider

If you are currently on a compounded GLP-1 or considering one, here are questions worth asking your doctor or prescribing provider.

What specific form of semaglutide or tirzepatide is in the compounded product and is it the same active ingredient used in the FDA-approved drug? Where is the compounding pharmacy sourcing its active pharmaceutical ingredients and are they from FDA-registered manufacturers? Is the compounding pharmacy licensed in your state, and are they a 503A or 503B facility? Given the current regulatory landscape, does your provider recommend transitioning to a branded product, and if so, what is the plan for dose conversion? Does your insurance cover any FDA-approved GLP-1 medications, and has a prior authorization been attempted? Would the Wegovy pill be an appropriate option, given its lower self-pay cost compared to injectable Wegovy?

Final Thoughts

The compounded GLP-1 story is not a simple good-versus-evil narrative. The shortage was real. The access gap was real. Many patients who could not afford or access branded medications genuinely benefited from compounded alternatives provided by legitimate pharmacies. At the same time, the rapid growth of mass-marketed compounding created real safety concerns that the data now supports.

Where things stand today: the regulatory environment has shifted decisively toward FDA-approved products. The Wegovy pill at $149 per month has lowered the price barrier significantly. The Novo/Hims deal has expanded telehealth access to branded products. And the FDA's enforcement actions show no signs of easing.

If you are currently on a compounded GLP-1, the most important step you can take right now is to have an honest conversation with your healthcare provider about transitioning to an FDA-approved product. And whether you use medication or not, the nutrition and exercise foundation remains the same: prioritize protein, lift weights and build the habits that will sustain your results long after the prescription runs out.

For guidance on that foundation, start with the GLP-1 diet plan and the protein calculator for women. If you need more structured guidance, our Protein Foundations program was designed to make getting optimal protein every day easier.

This article was last updated March 28, 2026. The regulatory landscape for compounded GLP-1 medications is evolving rapidly. I will continue to update this article as new enforcement actions, legal decisions and policy changes occur.